U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES Amendment No. 64

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of

Federal Regulations, Chapter I, Parts 30, 3 heretofore made by the licensee, a license is source, and special nuclear material designate deliver or transfer such material to persons aushall be deemed to contain the conditions spaplicable rules, regulations, and orders of the below.	31, 32, 3 hereby i ated belo uthorized pecified i	33, 34, 35, 36, 3 issued authorizinow; to use such of to receive it in a in Section 183 o	39, 40, and 70, and in ng the licensee to rece material for the purpos accordance with the reg of the Atomic Energy A	reliand eive, acc se(s) ar gulation Act of 19	ce on statements and representations quire, possess, and transfer byproduct, and at the place(s) designated below; to as of the applicable Part(s). This license 954, as amended, and is subject to all		
Licensee			In accordance with the letter dated				
			December 15, 2	,	/		
Bloomington Hospital			3. License number 13-10408-02 is amended in its entirety to read as follows:				
2. P.O. Box 1149			4. Expiration date	Noven	nber 30, 2020		
Bloomington, IN 47402			5. Docket No. 030-	-01644	4		
still.		Substitute of the Control of	Reference No.		AF.		
Byproduct, source, and/or special nuclear material	7.	Chemical and	l/or physical form	8.	Maximum amount that licensee may possess at any one time under this license		
Any byproduct material permitted by 10 CFR 35.100	A.	Any		A.	As needed		
B. Any byproduct material permitted by 10 CFR 35.200	B.	Any		B.	As needed		
C. Any byproduct material permitted by 10 CFR 35.300	C.	Any		C.	As needed (not to exceed one curie of iodine-131)		
D. Any byproduct material permitted by 10 CFR 35.400	D.	Sealed sources (Isotope Products Laboratories (Nuclear Associates) Model 67-800 Series, IsoRay, Model CS-1, North American Scientific, Inc., Model MED 3631, and MED 3633, Best Medical International, Inc., Model 2300 Series, 3M Health Physics Services, Model 6711 and Amersham Corp., Model CDC.CY102)		D.	Not to exceed 2000 millicuries for cesium-137, not to exceed 500 millicuries, for iodine-125 and not to exceed 1600 millicuries for palladium-103		
E. Any byproduct material permitted by 10 CFR 31.11	E.	Prepackaged	d Kits	E.	2 millicuries		

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	2	of	4
MATERIALS LICENSE SUPPLEMENTARY SHEET		License Number 13-10408-02				
		Docket or Reference Number 030-01644				
		Amendment No. 64				

9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. In-vitro studies.

CONDITIONS

- 10. A. Licensed material shall be used only at the licensee's facilities located at 605-625 West Second Street, Bloomington, Indiana.
 - B. Licensed material in Item 6.C., limited to strontium-89, phosphorus-32, and samarium-153, may be received and used at the licensee's facilities located at 2620 Cota Drive, Bloomington, Indiana.
- 11. The Radiation Safety Officer for this license is Patrick J. Byrne, DABR, CHP, DABSNM.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Bharati R. Kharkar, M.D.	10 CFR 35.300 (for iodine-131, oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), 35.400, and 31.11.
David Y. Lee, M.D.	10 CFR 35.300 (for iodine-131, oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), 35.400, and 31.11.
Sean M. Flynn, M.D.	10 CFR 35.100, 35.200, 10 CFR 35.300 (for iodine-131, oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.
Douglas D. Geiger, M.D.	10 CFR 35.100, 35.200, and 31.11.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION		PAGE	3	of	4
	License Number 13-10408-02				
MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-01644				
	Amendment No. 64				

Bruce N. Monson, M.D. 10 CFR 35.100, 35.200, 10 CFR 35.300 (for iodine-131, oral

administration of sodium iodide I-131 in quantities less than or

equal to 33 millicuries), and 31.11.

Mark A. Bisesi, M.D. 10 CFR 35.100, 35.200, 10 CFR 35.300 (for iodine-131, oral

administration of sodium iodide-131 in quantities less than or equal

to 33 millicuries), and 31.11.

Chris W. McGary, M.D. 10 CFR 35.100, 35.200, 10 CFR 35.300 (for iodine-131, oral

administration of sodium iodide I-131 in quantities less than or

equal to 33 millicuries), and 31.11.

T. L. Megremis, M.D. 10 CFR 35.100, 35.200, 10 CFR 35.300 (for iodine-131, oral

administration of sodium iodide I-131 in quantities less than or

equal to 33 millicuries), and 31.11.

John Alexander, M.D. 10 CFR 35.100, 35.200, 10 CFR 35.300 (for iodine-131, oral

administration of sodium iodide I-131 in quantities less than or

equal to 33 millicuries), and 31.11.

Jonathan A. Staser, M.D. 10 CFR 35.100, 35.200, 10 CFR 35.300 (for iodine-131, oral

administration of sodium iodide I-131 in quantities less than or

equal to 33 millicuries), and 31.11.

Gregory M. Sutliff, M.D. 10 CFR 35.100 and 35.200.

Jennifer Peterson Goldspiel, M.D. 10 CFR 35,100 and 35,200.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated June 11, 2010.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date ___ FEB 1 0 2011

Jack of

Tove L. Simmons

Materials Licensing Branch

Region III